Abstract
Hidradenitis suppurativa is a chronic inflammatory disorder of the follicular epithelium in the axilla, groin, peritoneum, and intertriginous areas that presents with painful nodules and abscesses. Due to the poorly understood etiology of the disorder, there are various different treatment options targeting proposed mechanisms of actions which results in a lot of trial and error to find the appropriate treatment plan. Clinicians must consider the whole patient while understanding the efficacy of the medication, possible adverse reactions, and patient compliance when creating a treatment plan, especially with the use of systematic biologics. This review aims to compare two currently FDA-approved biologic options for patients with moderate-to-severe hidradenitis suppurativa, adalimumab and secukinumab.
Included in
The Efficacy and Safety Profile of Adalimumab and Secukinumab in Treating Hidradenitis Suppurativa
Hidradenitis suppurativa is a chronic inflammatory disorder of the follicular epithelium in the axilla, groin, peritoneum, and intertriginous areas that presents with painful nodules and abscesses. Due to the poorly understood etiology of the disorder, there are various different treatment options targeting proposed mechanisms of actions which results in a lot of trial and error to find the appropriate treatment plan. Clinicians must consider the whole patient while understanding the efficacy of the medication, possible adverse reactions, and patient compliance when creating a treatment plan, especially with the use of systematic biologics. This review aims to compare two currently FDA-approved biologic options for patients with moderate-to-severe hidradenitis suppurativa, adalimumab and secukinumab.